Flu Vaccine Cut Hospitalizations Despite Drifted H3N2 Strain - Summary - MDSpire

Flu Vaccine Cut Hospitalizations Despite Drifted H3N2 Strain

Interim CDC estimates found the 2025–2026 vaccine reduced outpatient influenza visits by up to 41% and hospitalizations by up to 41%.

  • By

  • Kerri Miller

  • March 17, 2026

  • 5 min

Share

Objective:

To assess the effectiveness of the 2025–2026 seasonal influenza vaccine in reducing outpatient visits and hospitalizations due to influenza during the specified season.

Key Findings:
  • Vaccine reduced outpatient visits by 22% to 34% and hospitalizations by 30% among adults, while pediatric patients showed the strongest protection with 38% to 41% effectiveness.
  • Vaccine effectiveness against influenza A(H3N2) was 35% for outpatient visits and 38% for hospitalizations in adults.
  • Influenza B showed higher outpatient effectiveness estimates of 71% and 45% in different networks.
Interpretation:

Despite antigenic drift in circulating viruses, the vaccine effectively reduced influenza-related morbidity, particularly in pediatric populations, highlighting the need for continued vaccination efforts.

Limitations:
  • Preliminary results may change as the season progresses.
  • Unmeasured confounding factors were not modeled, which may affect results.
  • Potential misclassification of vaccination status could impact effectiveness estimates.
  • Limited sample sizes in certain strata affected estimates.
Conclusion:

Vaccination significantly reduced the risk of influenza-associated outpatient visits and hospitalizations, underscoring the importance of influenza vaccination for all eligible individuals, especially in light of antigenic drift.

Original Source(s)

Flu Vaccine Cut Hospitalizations Despite Drifted H3N2 Strain

  • by Kerri Miller

  • March 17, 2026

Related Content

Sleep Program Shifted Teen Circadian Timing

Two-week chronotherapy trial evaluates circadian phase, sleep duration, and alignment outcomes.

Sex Disparities May Persist in CF Despite Modulators

Review findings suggested female patients with cystic fibrosis may continue to experience worse pulmonary outcomes despite highly effective modulator therapy

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.